12:00 AM
Feb 11, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

BVdU regulatory update

FDA granted Orphan Drug designation for RP101 for use as an adjunct to treat pancreatic cancer. The nucleoside analog that enhances chemosensitivity and...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >